{"url_path":"/sec/cpix/8-k/2026-07-01/item-2-01","section_key":"item-2-01","section_title":"Item 2.01 ****Completion of Acquisition or Disposition of Assets.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-01","source_url":"https://www.sec.gov/Archives/edgar/data/1087294/0001104659-26-079871-index.html","accession_number":"0001104659-26-079871","cik":"0001087294","ticker":"CPIX","issuer_name":"CUMBERLAND PHARMACEUTICALS INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1087294/0001104659-26-079871-index.html","primary_entity_key":"0001087294","primary_entity_name":"CUMBERLAND PHARMACEUTICALS INC"},"word_count":288,"has_tables":true,"body_markdown":"** **\n\n**Item 2.01****Completion of Acquisition or Disposition of Assets.**\n\n \n\nOn the Closing Date, Cumberland\ncompleted the sale of the Assets to Nuvo and certain affiliates of Apotex for aggregate cash consideration to the Company of $100 million\npursuant to the terms of the Agreement. The Transaction was approved by the shareholders of the Company at the special meeting of the\nCompany’s shareholders held on June 24, 2026, as described in the definitive proxy statement filed by the Company with the SEC\non May 26, 2026.\n\n \n\nAttached hereto as Exhibit 99.2, and incorporated\nherein by reference, is unaudited pro forma financial information of the Company as of March 31, 2026, consisting of the unaudited pro\nforma condensed balance sheet as of March 31, 2026, and the unaudited pro forma condensed statements of operations for the years ended\nDecember 31, 2025 and 2024, and the three months ended March 31, 2026, giving effect to the Transaction. The unaudited pro forma financial\ninformation included as an exhibit to this Current Report on Form 8-K is presented for illustrative purposes only and is not necessarily\nindicative of what the Company’s actual financial position or results of operations would have been had the Transaction been completed\non the dates indicated. The unaudited pro forma financial information reflects adjustments, which are based upon estimates. The information\nupon which these adjustments and assumptions have been made is preliminary, and these kinds of adjustments and assumptions are difficult\nto make with complete accuracy. Moreover, the pro forma financial information does not reflect all costs that are expected to be incurred\nby the Company. Accordingly, the final accounting adjustments may differ materially from the pro forma information included as an exhibit\nto this Current Report on Form 8-K."}